Now I have sufficient anchors for calibration. Let me write the final review.

**Calibration Summary:**

**Round 1 (Bracketing):**
- Low band (<3.5, e.g., 1.67-3.40): Papers about generic medical classification, aircraft estimation, etc. — clearly weaker than this paper. This paper is well above 3.5.
- Middle band (3.5-7.5): Found M4oE (5.75), Eye Fairness (5.50), Scale-Aware Contrastive (6.50), Malenia (6.25) — these are the right comparison class.
- High band (>7.5, 7.67-8.00): LVSM, NoPoSplat, Transfusion — these are large-scale generative/3D papers far stronger than this paper.
- **Bracket:** 5.0–6.5

**Round 2 (Narrowing):**
Read full reviews of anchors:
- **M4oE (5.75, Accept)**: Similar MoE-for-medical-imaging paper. Accepted despite missing variance estimates. This paper has more comprehensive evaluation (ablation + hyperparameter study) and clearer motivation. Slightly stronger → anchor suggests 5.75–6.0.
- **Eye Fairness (5.50, Reject)**: Dataset paper. This paper has stronger technical contribution → above 5.50.
- **Scale-Aware Contrastive (6.50, Accept)**: Incremental but accepted. This paper has comparable novelty. → comparable or slightly below at 6.0.
- **Malenia (6.25, Accept)**: Strong zero-shot lesion segmentation. Comparable novelty level.

**Final score:** 6.0. The paper has a meaningful technical contribution (GALP + LGRF), strong evaluation across two datasets, and good ablation. However, the unvalidated "lesion proposal" framing and the undiscussed Grade 4 gap prevent it from reaching 6.5+. It is clearly above reject-range papers (5.0–5.5).

---

## Summary
This paper proposes an end-to-end multi-view diabetic retinopathy (DR) grading framework with two main modules: GALP, which generates "lesion proposals" from auxiliary classifier CAMs via top-K region selection, and LGRF, which fuses cross-view information using a gated mixture-of-experts mechanism with top-K weighted cross-view attention. The key claim is that self-generated proposals can substitute for external lesion/vessel annotations, reducing annotation dependence while maintaining SOTA or near-SOTA accuracy. Evaluated on MFIDDR (4-view) and DRTiD (2-view), the method achieves 83.9% Acc without external annotations (matching/surpassing several externally-informed baselines) and 84.6% Acc with optional lesion maps.

## Strengths
- **Self-derived proposals achieve SOTA-competitive results without external annotations.** On MFIDDR (Table 1), "Ours (w/o lesion)" achieves 83.9% Acc, outperforming CVSA (82.6%, vessel-annotated) and approaching WGLIN (84.2%, lesion-annotated). On DRTiD (Table 3), the end-to-end variant (76.0% Acc) beats CrossFIT (75.6%, uses OD/macular coordinates). This directly supports the central claim about reducing annotation dependence.
- **Cross-view expert routing with contextual gating is measurably beneficial.** The ablation (Table 4) isolates each component: removing the expert pool ("w/o Experts") drops accuracy from 83.9% to 82.6%, and removing GALP drops it to 82.7%, confirming both modules contribute beyond the backbone alone.
- **Cross-dataset validation with consistent results.** Evaluated on two datasets with different view counts (4 vs 2), resolutions (224×224 vs 512×512), and backbone pretraining (ImageNet vs EyePACS), showing robustness to varying capture protocols.
- **Comprehensive hyperparameter analysis.** Figure 3 systematically varies retention ratio α (0.2–1.0), number of routed experts K₂ (1–6), and total experts M (2–8), providing practical deployment guidance.

## Weaknesses

### Fatal
None.

### Major
- **The "lesion proposal" claim is asserted without direct validation.** GALP generates proposals by selecting top-K patches from CAMs derived from auxiliary classifiers. The paper states these "are more likely to contain lesion evidence" (line 95), but provides zero qualitative evidence: no overlay visualizations on fundus images, no comparison against the lesion segmentation masks that MFIDDR already provides (line 185), and no analysis of proposal precision/recall. CAMs highlight whatever is most discriminative for classification — this could be vessels, optic disc boundaries, or imaging artifacts rather than actual lesions. The method works empirically regardless, but the core narrative — that it "recovers small, low-contrast lesions" (line 44) — is an interpretation unsupported by the evidence presented.
- **Grade 4 (proliferative DR) performance is notably weak and undiscussed.** In Table 2, "Ours (w/o lesion)" achieves only 36.0% F1 on Grade 4 (the most clinically urgent category), far below CVSA's 64.1%. Even "Ours (with lesion)" at 51.6% F1 remains substantially below CVSA. The paper's overall framing of "matching or surpassing externally informed methods" is misleading when broken down by this grade, and the paper does not acknowledge or discuss this gap anywhere in the text.

### Minor
- **No variance estimates.** All results in Tables 1–4 are point estimates from a single train/test split, with no standard deviations or indication of multiple runs. The improvements over some baselines are small (e.g., +0.4% over CrossFIT on DRTiD). While single-run evaluation on fixed splits is common in this literature, variance information would help assess robustness.
- **Backbone choice not fully isolated from architectural contribution.** The method uses Swin-B while many baselines use weaker backbones (ResNet-50, VGG-19, CNN hybrids). The "w/o GALP" ablation (Swin-B with LGRF but no proposals, 82.7%) already exceeds most end-to-end baselines, suggesting the backbone carries part of the improvement. A backbone-controlled comparison (e.g., re-implementing MVCINN with Swin-B) would disentangle these factors.

### Trivial
- **Incomplete training hyperparameters.** The paper specifies backbone, patch size, loss weights, and expert configuration but omits optimizer, learning rate, schedule, weight decay, batch size, epochs, data augmentation, and random seeds, hindering reproducibility.

## Nice-to-Haves
- Visualize lesion proposals overlaid on fundus images alongside ground-truth lesion masks (available in MFIDDR) to directly validate the proposal quality.
- Clarify why LGRF fuses only with the adjacent (cyclic) view rather than all other views, and how view ordering is determined.
- Report results over multiple random seeds (3–5) with means and standard deviations.

## Removed Points
- **Equation (3) notation issue (superscript/subscript).** Parser formatting artifact, not a substantive error in the original submission.
- **"Externally informed" framing as a straw man.** The paper acknowledges (lines 39–40, 185) that several baselines use model-generated rather than clinician-annotated maps. The distinction between end-to-end integration vs. external preprocessing pipelines is real and the paper engages with it.
- **Resolution difference between datasets (224 vs 512).** The paper explicitly notes this follows prior work conventions on each dataset. Not a flaw.
- **Inference-time proposal generation unclear.** The paper states (line 9) proposals are generated "during training and inference." At inference, the auxiliary classifier's predicted grade is used for GEMs — standard practice described in the method.
- **"Ours (with lesion)" uses model-generated masks not clinician labels.** The paper states (lines 185, 208) these are model-generated segmentation masks from the dataset, directly addressing this concern.

## Novel Insights
The harsh critic's observation that LGRF's adjacent-view-only fusion (view i fuses only with view i+1, not all other views) is architecturally noteworthy but under-explored in the paper. For 4-view data, this design means each view receives cross-view information from only one neighboring view. Whether a full pairwise fusion would improve results, or whether the cyclic design is sufficient, is not empirically tested. This is a potentially valuable design-space question for future work.

## Suggestions
1. Add a qualitative figure (or supplementary) showing lesion proposals overlaid on fundus images, compared against the lesion segmentation masks available in MFIDDR, to validate the core claim.
2. Acknowledge and discuss the Grade 4 performance gap — explain why it occurs and whether it stems from proposal quality for severe cases.
3. Report results over 3–5 random seeds with means and standard deviations.
4. Provide complete training hyperparameters (optimizer, LR schedule, epochs, augmentation, seeds) in the supplement.

## Score and Decision
**Round 1 bracket:** 5.0 – 6.5
**Round 2 narrowing:** Compared against M4oE (5.75, Accept), Eye Fairness (5.50, Reject), Scale-Aware Contrastive (6.50, Accept), and Malenia (6.25, Accept). The paper is slightly stronger than M4oE due to more comprehensive evaluation and clearer motivation, but the unvalidated lesion-proposal claim and undiscussed Grade 4 gap keep it below 6.5. It is clearly above reject-range papers (5.0–5.5).

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>